Harnessing the power of vaccines using the public and private sector: A 21<sup>st</sup> century model for international development


#### Dr. Seth Berkley, CEO GAVI Alliance

Wellcome Trust – Cambridge Centre for Global Health Research Inaugural Lecture

Cambridge, 2 May 2013




### Vaccine development timeline: 1798-1910






### Vaccine development timeline: 1910-





### Cumulative number of vaccines developed





## Unprecedented results from vaccines: 1980-2010

	1980	2010	Change
Global population	4,424,952	6,852,721	+54%
Diphtheria cases:	97,511	4,187	<b>-95%</b>
Measles cases:	4,211,431	327,368	<b>-92%</b>
Pertussis cases:	1,982,355	156,675	<b>-92%</b>
Polio cases:	52,795	1,348	<b>-97%</b>
Tetanus cases:	114,251	4,925	<b>-95%</b>



### GAVI mission and strategic goals 2011–2015

To save children's lives and protect people's health by increasing access to immunisation in poor countries

#### The vaccine goal

Accelerate the uptake and
use of underused and new vaccines

2

The health systems goal Contribute to strengthening the capacity of integrated health systems to deliver immunisation



#### The financing goal

Increase the predictability of global financing and improve the sustainability of national financing for immunisation




#### The market shaping goal

Shape vaccine markets to ensure adequate supply of appropriate, quality vaccines at low and sustainable prices



## Infectious causes of child deaths 1–59 months GAVI-eligible countries – 2010 estimates






### 2013 Measles rubella 2013 **HPV** 2011 Meningitis A 2009 Pneumococcal 2008 Rotavirus 2007 Measles 2006 **Pentavalent** 2002 **Hib** 2001 Yellow fever 2001 Hepatitis B




### GAVI supports the world's poorest countries

#### Type and value of support, 2000–2012






### GAVI support for pneumococcal vaccine






### **IB-VPD Surveillance Network**






### Early impact of pneumococcal vaccine in Kenya

Cumulative admissions of children under five for invasive pneumococcal disease, Kilifi District Hospital



Source: Pneumoccocal Conjugate Vaccine Impact Study Kilifi. http://www.kemri-wellcome.org/pcvis-current%20disease%20surveillance










### Taking stock: the immunisation gap (73 GAVI-supported countries)

75 million surviving newborns in 2011:



#### Percentage of surviving infants (%)


Note: Coverage refers to the final dose of each vaccine.

Sources: WHO/UNICEF coverage from July 2012; United Nations, Department of Economic and Social Affairs, Population Division (2011). World Population Prospects: The 2010 Revision, CD-ROM Edition. Country income categories (World Bank) as of July 2012 (2011 GNI per capita)



### Introduction of HPV vaccine


#### Status: prior to GAVI



Source: Courtesy of Progress in Cervical Cancer Prevention: The CCA Report Card, August 2011



### Cervical cancer mortality




Source: Globocan 2008, International Agency for Research on Cancer. Courtesy of Progress in Cervical Cancer Prevention: The CCA Report Card, August 2011




# Higher incidence and mortality from cervical cancer in less developed regions

Comparison of cervical cancer incidence and mortality less developed vs more developed regions









### GAVI Alliance: a partnership












THE WORLD BANK



BILL& MELINDA GATES foundation



# The GAVI Alliance: 21st century model of development






### Innovative partnerships

Resetting...

- The way we think of development public private partnership models
- The way we do development market-shaping, innovative financing, etc.
- The "donor recipient" model sustainability, ownership/co-financing
- Catalysing the introduction of new technologies



### How the co-financing policy works






# Projected vaccine costs as a share of projected public spending on health, 2015

New Co- financing Categories	Per capita government spending on health	Government spending on health as % of government spending	Government spending as % of GDP	Vaccines as % of government spending on health	
				2010	2015
Low income	\$14.83	10.0%	25.0%	4.2%	6.3%
Intermediate	\$35.84	9.1%	31.2%	1.5%	2.2%
Graduating	\$107.43	8.7%	37.0%	0.5%	0.6%

Data Sources: World Bank/ WHO National Health Accounts/ GAVI Demand Forecast Note: Eritrea, India, Korea D.R., Somalia and Zimbabwe excluded from analysis



### Ramsey pricing






#### GAVI countries birth cohort

### Non-GAVI countries birth cohort

### 2012 global birth cohort: 135 million

# GAVI countries birth cohort: **80 million**






# Changing the mindset of the vaccine manufacturing industry





### **Tiered pricing**



- <sup>1</sup> The UNICEF/GAVI price is the weighted average across suppliers and presentations of pentavalent vaccine and reflects the cost of whole-cell pertussis vaccine; the US public market price is lowest total price per dose for separate DTP, hepB and Hib vaccines and reflects the cost of acellular pertussis vaccine.
- <sup>2</sup> The UNICEF/GAVI price is the tail price under the Advanced Market Commitment (AMC); the US public market price is for 13-valent vaccine.
- <sup>3</sup> The UNICEF/GAVI price is the weighted average assuming 3-dose equivalence; the US public market price is the average assuming 3-dose equivalence.



### Vaccine supply

**2001 – Vaccine supply:** 5 suppliers from 5 countries


Countries of vaccine suppliers

2001



### Vaccine supply

**2012 – Vaccine supply:** 10 suppliers from 9 countries



# GAVI's innovative finance mechanisms are redefining funding for development



IFFIm converts long-term government commitments into immediately available cash resources by issuing "vaccine bonds" on the capital markets. This accelerates the availability and predictability of funds – enabling GAVI to double its spending on immunisation programmes



AMC accelerates the development and manufacture of vaccines for developing countries at affordable prices. In an AMC, donors commit funds to guarantee vaccine prices

GAVI Matching Fund The GAVI Matching Fund is a private sector engagement programme designed to leverage funds, resources and expertise from the private sector



# 2012 Performance-based financing

- 2009 Health system funding platform
- Health system strengthening
   Injection safety support



## GAVI catalyses the new partnerships and the introduction of new technologies








### GAVI Challenges





### More than 22 million children still unimmunised


Global number of under-five children unimmunised with 3 doses of DTP, 2011





Note: Revised figures for 2011 (July 2012) Source: WHO/UNICEF vaccine coverage estimates (July 2012)

### GAVI challenges: Reaching the hardest to reach




Patterns of DTP 3 vaccination coverage across wealth quintiles since 2005



Source: DHS and MICS data (since 2005) Courtesy: Save the Children UK, 2012

#### The challenge of rigorous data - DTP3 coverage: Ethiopia





# GAVI challenges: potential solutions for improved data

Improved denominator estimates:

 Vital registration, regular conduct of censuses; satellite imagery, small area analysis of household survey.

Innovation in use of biomarkers, technology and triangulation:

 Development of integrated surveillance tools that would allow measurement of impact across multiple programs



### Vaccine supply chain: seeking efficiencies










# Cost effective improvements to supply chain management

- Improving stock management through digital technology platforms
- Accelerate the introduction of standards for technology that will help with tracking and tracing vaccines: e.g. 2-d bar codes
- Learn from open source systems: e.g. Geocaching







#### TED Challenge: Tracking & Tracing Vaccines in the

Vaccines in the GAVI Alliance Supply Chain






# New vaccines?

Malaria vaccine? Inactivated polio vaccine? Cholera vaccine? Cancer vaccines? Malaria vaccine? Dengue vaccine? **Tuberculosis vaccine? HIV vaccine?** 




#### Malaria vaccine Phase 3 evaluation





#### With new antibodies, new targets




**Cancer vaccines Hepatitis B** Human papillomavirus Helicobacter pylori? **Epstein-barr?** ???



#### A short history of immunisation milestones

WHO vaccine recommendations and GAVI country coverage rates



## The fully immunised Child



# Approximately 50% in 2030

Approximately

**100/0 of children will be** fully immunised in 2015

## Thank you



